If you would like to submit a blog post for consideration, please email admin@healthcert.com

New Eczema Treatment Puts Sufferers Into Remission

A new eczema treatment approved by the Therapeutic Goods Administration has been shown to put chronic sufferers into remission.

In a two-year trial of the drug Dupixent, some patients’ eczema completely disappeared within eight weeks.

Dupixent is a form of biologics: antibodies manufactured in genetically modified yeast cultures that disrupt molecular targets.

During the trial, 85 per cent of patients experienced a 50 per cent reduction in symptoms of atopic dermatitis. Combined with a topical steroid treatment, these patients entered 100 per cent remission.

Eczema can profoundly detriment sufferers’ quality of life, leading to self-esteem issues that manifest into reclusiveness, anxiety and depression. Effective therapies are limited, and a new treatment for the condition has not been released in over 15 years.

Dupixent is a “safer long-term solution”, according to the researchers who conducted the trial. However, it is yet to be listed on the Pharmaceutical Benefits Scheme, which would bring its cost down to $37 per prescription.

Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy.

Read more recent research on eczema.


Murphy, L. (9 February 2018.) New eczema treatment putting sufferers into remission. 9news.

Interested in General Dermatology?

The HealthCert Professional Diploma of General Dermatology will teach you how to manage all major dermatological conditions in primary care. The courses are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The program is delivered online.

Clinical Procedures Certificate Courses in Australia

One comment on “New Eczema Treatment Puts Sufferers Into Remission

Leave a Reply

Your email address will not be published. Required fields are marked *